Home
  >  
Section 58
  >  
Chapter 57,417

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections

Shields, R.K.; Potoski, B.A.; Haidar, G.; Hao, B.; Doi, Y.; Chen, L.; Press, E.G.; Kreiswirth, B.N.; Clancy, C.J.; Nguyen, M.H.

Clinical Infectious Diseases An Official Publication of the Infectious Diseases Society of America 63(12): 1615-1618

2016

ISSN/ISBN: 1537-6591
PMID: 27624958
DOI: 10.1093/cid/ciw636
Accession: 057416477
Download citation:  
Text
  |  
BibTeX
  |  
RIS
Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.

PDF emailed within 0-6 h: $19.90




Related References

Rathish, B.; Wilson, A.; Warrier, A.; Prakash, S.; Babu, R.; Joy, S. 2021: Clinical Outcomes in Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime-Avibactam: a Single-Center Observational Study Cureus 13(2): E13081
Shields, R.K.; Nguyen, M.H.; Hao, B.; Kline, E.G.; Clancy, C.J. 2018: Colistin Does not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae in Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance Antimicrobial Agents and ChemoTherapy 62(8)
King, M.; Heil, E.; Kuriakose, S.; Bias, T.; Huang, V.; El-Beyrouty, C.; McCoy, D.; Hiles, J.; Richards, L.; Gardner, J.; Harrington, N.; Biason, K.; Gallagher, J.C. 2017: Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Antimicrobial Agents and ChemoTherapy 61(7)
Jorgensen, S.C.J.; Trinh, T.D.; Zasowski, E.J.; Lagnf, A.M.; Bhatia, S.; Melvin, S.M.; Simon, S.P.; Rosenberg, J.R.; Steed, M.E.; Estrada, S.J.; Morrisette, T.; Davis, S.L.; Rybak, M.J. 2020: Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime-Avibactam Infectious Diseases and Therapy 9(2): 291-304
Liao, Q.; Deng, J.; Feng, Y.; Zhang, W.; Wu, S.; Liu, Y.; Che, H.; Xie, Y. 2022: Emergence of ceftazidime-avibactam resistance due to a novel blaKPC-2 mutation during treatment of carbapenem-resistant Klebsiella pneumoniae infections Journal of Infection and Public Health 15(5): 545-549
Shields, R.K.; Nguyen, M.H.; Chen, L.; Press, E.G.; Kreiswirth, B.N.; Clancy, C.J. 2018: Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections Antimicrobial Agents and ChemoTherapy 62(5)
Shields, R.K.; Chen, L.; Cheng, S.; Chavda, K.D.; Press, E.G.; Snyder, A.; Pandey, R.; Doi, Y.; Kreiswirth, B.N.; Nguyen, M.H.; Clancy, C.J. 2017: Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections Antimicrobial Agents and ChemoTherapy 61(3)
Alraddadi, B.M.; Saeedi, M.; Qutub, M.; Alshukairi, A.; Hassanien, A.; Wali, G. 2019: Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae Bmc Infectious Diseases 19(1): 772
Van Duin, D.; Lok, J.J.; Earley, M.; Cober, E.; Richter, S.S.; Perez, F.; Salata, R.A.; Kalayjian, R.C.; Watkins, R.R.; Doi, Y.; Kaye, K.S.; Fowler, V.G.; Paterson, D.L.; Bonomo, R.A.; Evans, S. 2018: Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 66(2): 163-171
Ackley, R.; Roshdy, D.; Meredith, J.; Minor, S.; Anderson, W.E.; Capraro, G.A.; Polk, C. 2020: Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections Antimicrobial Agents and ChemoTherapy 64(5)
Krapp, F.; Grant, J.L.; Sutton, S.H.; Ozer, E.A.; Barr, V.O. 2017: Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation International Journal of Antimicrobial Agents 49(6): 770-773
Gu, J.; Xu, J.; Zuo, T.-T.; Chen, Y.-B. 2021: Ceftazidime-avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae: Ceftazidime-avibactam against CR-KP infections Journal of Global Antimicrobial Resistance 26: 20-25
Zhang, P.; Shi, Q.; Hu, H.; Hong, B.; Wu, X.; Du, X.; Akova, M.; Yu, Y. 2020: Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China Clinical Microbiology and Infection: the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 26(1): 124.E1-124.E4
Fiore, M.; Alfieri, A.; Di Franco, S.; Pace, M.C.; Simeon, V.; Ingoglia, G.; Cortegiani, A. 2020: Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: a Systematic Review and Network Meta-Analysis Antibiotics 9(7)
Han, X.; Shi, Q.; Mao, Y.; Quan, J.; Zhang, P.; Lan, P.; Jiang, Y.; Zhao, D.; Wu, X.; Hua, X.; Yu, Y. 2021: Emergence of Ceftazidime/Avibactam and Tigecycline Resistance in Carbapenem-Resistant Klebsiella pneumoniae Due to In-Host Microevolution Frontiers in Cellular and Infection Microbiology 11: 757470
Zou, C.; Wei, J.; Shan, B.; Chen, X.; Wang, D.; Niu, S. 2020: In vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Carbapenem-resistant Enterobacteriaceae Isolates Collected from Three Secondary Hospitals in Southwest China Between 2018 and 2019 Infection and Drug Resistance 13: 3563-3568
Tu, Y.; Wang, D.; Zhu, Y.; Li, J.; Jiang, Y.; Wu, W.; Li, X.; Zhou, H. 2022: Emergence of a KPC-90 Variant that Confers Resistance to Ceftazidime-Avibactam in an ST463 Carbapenem-Resistant Pseudomonas aeruginosa Strain Microbiology Spectrum 10(1): E0186921
Xu, M.; Qian, C.; Jia, H.; Feng, L.; Shi, S.; Zhang, Y.; Wang, L.; Cao, J.; Zhou, T.; Zhou, C. 2022: Emergence of Ceftazidime-Avibactam Resistance and Decreased Virulence in Carbapenem-Resistant ST11 Klebsiella pneumoniae During Antibiotics Treatment Infection and Drug Resistance 15: 6881-6891
Faccone, D.; de Mendieta, J.M.; Albornoz, E.; Chavez, M.; Genero, F.; Echegorry, M.; Ceriana, P.; Mora, A.; Seah, C.; Corso, A.; Melano, R.G.; Pasteran, F. 2022: Emergence of KPC-31, a KPC-3 Variant Associated with Ceftazidime-Avibactam Resistance, in an Extensively Drug-Resistant ST235 Pseudomonas aeruginosa Clinical Isolate Antimicrobial Agents and ChemoTherapy 66(11): E0064822
Wu, G.; Abraham, T.; Lee, S. 2016: Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 63(8): 1147-1148